SEC Form 3 · accession 0001209191-19-010151
PROTEOSTASIS THERAPEUTICS, INC. · PTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sheila Wilson
Officer — Chief Operating Officer
Period of report
Feb 5, 2019
Accepted (ET)
Feb 14, 2019 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001445283
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 18,586 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.98 | holding | — | — | — | — | Nov 1, 2026 | Common Stock | 60,000 | — | D |
| Employee Stock Option (Right to Buy)F2 | $14.72 | holding | — | — | — | — | Mar 1, 2027 | Common Stock | 15,000 | — | D |
| Employee Stock Option (Right to Buy)F3 | $3.11 | holding | — | — | — | — | Mar 1, 2028 | Common Stock | 24,000 | — | D |
Explanation of responses
- F1These securities shall vest and become exercisable in a series of installments, with the first installment becoming exercisable for 25% of the underlying common stock on November 1, 2017, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on November 1, 2026, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
- F2These securities shall vest and become exercisable in a series of installments, with the first installment becoming exercisable for 25% of the underlying common stock on March 1, 2018, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 1, 2027, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
- F3These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 1, 2019, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 1, 2028, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
Remarks
Exhibit List - Exhibit 24.1 - Limited Power of Attorney